Skip to main content
Fig. 5 | Arthritis Research & Therapy

Fig. 5

From: Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study

Fig. 5

Mean change in work productivity and activity impairment outcome measures by Psoriatic Arthritis Disease Activity Score (PASDAS) states at weeks 16, 52 and 104. Data are from mixed model for repeated measures analysis. *P < 0.0001; †P < 0.001; §P < 0.01 and ‡P < 0.05 versus HDA. n = number of patients with measurements at both baseline and post-baseline visits; N = number of patients in each group of the specified analysis set. HDA High disease activity, LDA Low disease activity, LS Least squares, MoDA Moderate disease activity. Week 16: N = 32 (remission), N = 53 (LDA), N = 128 (MoDA) and N = 69 (HDA); week 52: N = 44 (remission), N = 81 (LDA), N = 112 (MoDA) and N = 21 (HDA); week 104: N = 47 (remission), N = 81 (LDA), N = 95 (MoDA) and N = 13 (HDA). Analytic data were pooled across treatment arms

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us